A prognostic 3‐long noncoding RNA signature for patients with gastric cancer

@article{Cheng2018AP3,
  title={A prognostic 3‐long noncoding RNA signature for patients with gastric cancer},
  author={Peng Cheng},
  journal={Journal of Cellular Biochemistry},
  year={2018},
  volume={119},
  pages={9261 - 9269}
}
  • Peng Cheng
  • Published 3 August 2018
  • Medicine, Biology
  • Journal of Cellular Biochemistry
Current studies showed that long noncoding RNAs (lncRNAs) may act as prognostic biomarkers in a variety of cancers. The aim of this study was to identify and assess a prognostic lncRNA signature in patients with gastric carcinoma (GC). LncRNAs expression profiles and corresponding clinicopathological data for 350 patients with GC were obtained from The Cancer Genome Atlas (TCGA), and the least absolute shrinkage and selection operator Cox (LASSO Cox) regression model was used to identify the… 
Identification of 4‐lncRNA prognostic signature in head and neck squamous cell carcinoma
TLDR
A robust 4‐lncRNA prognostic signature for HNSCC was developed that might provide a novel powerful prognostic biomarker for precision oncology and outperformed those previously well‐established prognostic factors.
An Integrated Three-Long Non-coding RNA Signature Predicts Prognosis in Colorectal Cancer Patients
TLDR
Evidence is provided that the three-lncRNA signature could serve as an independent biomarker to predict prognosis in CRC and the Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated that these DElncRNAs were involved with several cancer-related pathways.
Identification of a 6‐lncRNA prognostic signature based on microarray re‐annotation in gastric cancer
TLDR
The 6‐lncRNA signature can effectively make the prognosis evaluation of GC patients, and robust likelihood‐based survival and least absolute shrinkage and selection operator (LASSO) models were used to establish a 6-lnc RNA signature with prognostic value.
Identification of key lncRNAs as prognostic prediction models for colorectal cancer based on LASSO.
TLDR
This study shows that the six lncRNAs model can improve the survival prediction mechanism of patients with CRC and provide help for patients through personalized treatment.
Discovery of a novel three-long non-coding RNA signature for predicting the prognosis of patients with gastric cancer.
TLDR
A robust three-lncRNA model is established to predict the OS of GC patients, which might benefit the clinical decision making for personalized treatment and prognostic prediction for GC patients.
Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients
TLDR
A simple noninvasive prognostic signature was established for preoperative prediction of disease free survival in GC patients and might predict the individual mortality risk of diseasefree survival without pathological information and facilitate individual treatment decision-making.
Novel Prognostic Model for Gastric Cancer using 13 Co-Expression Long Non-Coding RNAs (LncRNAs)
  • Xi Luo, Kuan-Jui Su, +4 authors F. Yang
  • Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2020
TLDR
The clinical-gene model containing 13 co-expression lncRNAs identified by the comprehensive method and 3 clinical factors including molecular subtype, recurrence status and operation type was the found to be the optimal model in the study.
The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma
TLDR
Potential molecular biological regulation pathways and prognostic biomarkers by the ceRNA regulatory network are revealed and might be helpful to predict the individual mortality risk for HCC patients.
lncRNA Profiles Enable Prognosis Prediction and Subtyping for Esophageal Squamous Cell Carcinoma
TLDR
The findings indicated the potentials of lncRNA markers in the prognosis, molecular subtyping, and EMT of ESCC.
Long non-coding RNAs as prognostic biomarkers in papillary renal cell carcinoma
TLDR
The aim of the present study was to identify long non-coding RNA (lncRNA)-based prognostic biomarkers in papillary renal cell carcinoma (pRCC) and serve as a foundation for further investigations into the underlying mechanism of tumorigenesis and progression of pRCC.
...
1
2
3
...

References

SHOWING 1-10 OF 43 REFERENCES
Comprehensive analysis of a novel four-lncRNA signature as a prognostic biomarker for human gastric cancer
TLDR
This study indicates that this novel lncRNA expression signature may be a useful biomarker of the prognosis for GC patients, based on bioinformatics analysis.
Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis
TLDR
An innovative 12-lncRNA signature was established, and it was significantly associated with the disease free survival (DFS) in the training dataset, and a group of pathways related to drug resistance and cancer metastasis significantly enriched in the high risk patients.
Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas
TLDR
The findings indicated that the newly discovered four-miRNA signature may be an effective independent prognostic factor for the prediction of patients with lower-grade gliomas.
lncRNA Gene Signatures for Prediction of Breast Cancer Intrinsic Subtypes and Prognosis
TLDR
Although lncRNAs can independently predict breast cancer subtypes with satisfactory accuracy, a combined gene signature including both coding and non-coding genes will give the best clinically relevant prediction performance.
Functional long non-coding RNAs associated with gastric cancer susceptibility and evaluation of the epidemiological efficacy in a central Chinese population.
TLDR
Findings showed rs4784659, rs579501 and rs1859168 reduced the susceptibility of gastric cancer.
Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer
TLDR
The results suggest that the PANDAR is a powerful diagnostic and therapeutic marker for patients with GC and, combined with other chemotherapeutics, may have distinct antitumour effects.
Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
TLDR
LINC01234 expression was significantly upregulated in gastric cancer tissues and was associated with larger tumor size, advanced TNM stage, lymph node metastasis, and shorter survival time, and Mechanistic investigations indicated that LINC01 234 functioned as a ceRNA for miR-204-5p, thereby leading to the derepression of its endogenous target core-binding factor β (CBFB).
Construction and analysis for differentially expressed long non-coding RNAs and MicroRNAs mediated competing endogenous RNA network in colon cancer
TLDR
The dysregulated lncRNA-associated ceRNA network was constructed in colon cancer based on bioinformatics generated from miRanda, PicTar, TargetScan, miRDB and miRcode, including 9 colon cancer-specific lncRNAs, 13 miRNAS and 70 mRNAs.
Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo‐YAP signaling
TLDR
LncRNA MALAT1 presented an extremely high expression level in pancreatic cancer tissues and cells and the in vivo assay was found that the tumor to be small in size and volume, and the expression of Ki‐67 was decreased.
LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer.
TLDR
ZEB1-AS1 served as oncogenic roles in the regulation of gastric cancer cells migration, invasion and EMT process through modulating ZEB1.
...
1
2
3
4
5
...